ISW

In Silico World: Lowering barriers to ubiquitous adoption of In Silico Trials

Abstract

The overall aim of the In Silico World project is to accelerate the uptake of modelling and simulation technologies for the development and regulatory assessment of all kind of medical products. This will be achieved by supporting the trajectory of a number of In Silico Trials solutions through development, validation, regulatory approval, optimisation, and commercial exploitation. These solutions, already developed to different stages, target different medical specialities (endocrinology, orthopaedics, infectiology, neurology, oncology, cardiology), different diseases (osteoporosis, dynapenia-sarcopenia, tuberculosis, multiple sclerosis, mammary carcinoma, arterial stenosis, etc.), and different types of medical products (medicinal products, medical devices, and Advanced Therapeutic Medicinal Products). In parallel the consortium will work with a large multi-stakeholder advisory board to form a community of Practice around In Silico Trials, where academics, industry experts, regulators, clinicians, and patients can develop consensus around Good modelling Practices. As the solutions under development move toward their commercial exploitation, the ISW consortium will make available to the Community of Practice a number of resources (technologies, validation data, first in kind regulatory decisions, technical standardisation plans, good modelling practices, scalability and efficiency-improving solutions, exploitation business models, etc.) that will permanently lower barriers to adoption for any future development.

Project details

Unibo Team Leader: Marco Viceconti

Unibo involved Department/s:
Dipartimento di Ingegneria Industriale
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

Coordinator:
ALMA MATER STUDIORUM - Università di Bologna(Italy)

Other Participants:
Erasmus Universitair Medisch Centrum Rotterdam (Netherlands)
Università  degli Studi di CATANIA (Italy)
Virtual Physiological Human Institute For Integrative Biomedical Research Vzw (Belgium)
InSilicoTrials Technologies SPA (Italy)
RSscan International (Belgium)
Eindhoven University Of Technology - Technische Universiteit Eindhoven (Netherlands)
Budapest University Of Technology And Economics - Budapesti Műszaki És Gazdaságtudományi Egyetem (Hungary)
Universite De Liege (Belgium)
Mimesis Srl (Italy)
Universiteit Van Amsterdam (Netherlands)
Sano - Centrum Zindywidualizowanej Medycyny Obliczeniowej - Międzynarodowa Fundacja Badawcza (Poland)
Katholieke Universiteit Leuven (Belgium)
DIN Deutsches Institut für Normung e. V. (Germany)

Total Eu Contribution: Euro (EUR) 7.646.012,25
Project Duration in months: 48
Start Date: 01/01/2021
End Date: 31/12/2024

Cordis webpage
Project website

Industry, innovation and infrastructure This project contributes to the achievement of the Sustainable Development Goals of the UN 2030 Agenda.

UE flag This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016503